Department of Plastic Surgery, Cleveland Clinic, Cleveland, OH 44195, USA.
Microsurgery. 2013 Jan;33(1):43-50. doi: 10.1002/micr.22023. Epub 2012 Jul 23.
Cellular and vascularized bone marrow cells have been used to induce donor-specific chimerism in various models of composite tissue allotransplantation. Although thymus transplantation has been reported in the literature, the effect of thymus transplantation on chimerism levels in vascularized bone containing composite tissue allotransplantation has not been reported. In this study, a new method for composite vascularized sternal bone marrow transplant model is descried that can be applied to augment chimerism after transplantation. A total of seven composite osseomusculocutaneous sternum, ribs, thymus, pectoralis muscles, and skin transplantations were performed in two groups. The first group (n = 5) was designed as an allotransplantation group and the second group (n = 2) was designed as an isotransplantation group. Composite osseomusculocutaneous sternum, ribs, thymus, and pectoralis muscles allografts were harvested on the common carotid artery and external jugular vein and a heterotopic transplantation was performed to the inguinal region of the recipient rat. Cyclosporine A monotherapy was administered in order to prevent acute and chronic allograft rejection. Animals sacrificed when any sign of rejection occurred. The longest survival was 156 day post-transplant. Assessment of bone marrow cells within sternum bone component and flow cytometry analysis of donor-specific chimerism in the peripheral blood of recipients were evaluated. Our results showed that this composite allograft carried 7.5 × 10(6) of viable hematopoietic cells within the sternum component. At day 7 post-transplant chimerism was developed in T-cell population and mean level was assessed at 2.65% for RT1(n) /CD4 and at 1.0% for RT1(n) /CD8. In this study, a new osseomusculocutaneous sternum, ribs, thymus, pectoralis muscle, and skin allotransplantation model is reported which can be used to augment hematopoietic activity for chimerism induction after transplantation.
细胞和血管化的骨髓细胞已被用于在各种复合组织同种异体移植模型中诱导供体特异性嵌合体。尽管文献中已有胸腺移植的报道,但在含有血管化骨的复合组织同种异体移植中,胸腺移植对嵌合体水平的影响尚未报道。在这项研究中,描述了一种新的复合血管化胸骨骨髓移植模型的方法,该方法可用于增强移植后的嵌合体。在两组中进行了总共 7 例复合骨-肌肉-皮胸骨、肋骨、胸腺、胸肌和皮肤移植。第一组(n=5)设计为同种异体移植组,第二组(n=2)设计为同基因移植组。复合骨-肌肉-皮胸骨、肋骨、胸腺和胸肌同种异体移植物在颈总动脉和颈外静脉上收获,并在受体大鼠的腹股沟区进行异位移植。为了防止急性和慢性同种异体移植物排斥反应,给予环孢素 A 单药治疗。当出现排斥反应的任何迹象时,动物被处死。移植后最长存活时间为 156 天。评估胸骨骨成分中的骨髓细胞,并对受体外周血中供体特异性嵌合体进行流式细胞术分析。我们的结果表明,这种复合同种异体移植物在胸骨成分中携带 7.5×10(6)个有活力的造血细胞。在移植后 7 天,T 细胞群中出现嵌合体,RT1(n)/CD4 的平均水平为 2.65%,RT1(n)/CD8 的平均水平为 1.0%。在这项研究中,报道了一种新的骨-肌肉-皮胸骨、肋骨、胸腺、胸肌和皮肤同种异体移植模型,可用于增强移植后诱导嵌合体的造血活性。